26.1 Hematologic Emergencies in the ICU: HIT, DIC, TMA & Anticoagulant Reversal

Heparin-Induced Thrombocytopenia (HIT)

Heparin-Induced Thrombocytopenia (Type II HIT) is a life-threatening, immune-mediated prothrombotic adverse drug reaction. Unlike the benign, non-immune Type I heparin-associated thrombocytopenia—a mild, transient drop occurring within the first 48 to 72 hours due to direct platelet agglutination—Type II HIT is driven by immunoglobulin G (IgG) autoantibodies directed against multimolecular complexes of platelet factor 4 (PF4) and unfractionated heparin (UFH) or, less frequently, low-molecular-weight heparin (LMWH).

Pathophysiology and Thrombus Generation

When heparin binds to PF4 released from platelet alpha granules, conformational changes expose neoepitopes on PF4. Pathogenic IgG antibodies bind these PF4-heparin complexes, and their Fc domains subsequently cross-link platelet Fc$\gamma$RIIa receptors. This cross-linking triggers intense platelet activation, releasing procoagulant microparticles, additional PF4, and excessive thrombin. Concurrently, PF4 binds to heparan sulfate on endothelial surfaces, enabling antibody binding and subsequent endothelial injury and tissue factor expression. The net result is a consumptive thrombocytopenia accompanied by a paradoxically profound hypercoagulable state ("white clot syndrome"), causing both venous thromboembolism (deep vein thrombosis, pulmonary embolism, cerebral venous sinus thrombosis) and arterial thrombosis (limb ischemia, stroke, acute myocardial infarction, mesenteric ischemia).

Clinical Risk Stratification: The 4T Scoring System

The pretest probability of HIT should be systematically calculated using the validated 4T Score:

1. Thrombocytopenia:
   • 2 points: Platelet count fall $> 50\%$ and platelet nadir $\ge 20 \times 10^9/\text{L}$.
   • 1 point: Platelet count fall $30\%$ to $50\%$ or platelet nadir $10$ to $19 \times 10^9/\text{L}$.
   • 0 points: Platelet count fall $< 30\%$ or platelet nadir $< 10 \times 10^9/\text{L}$.
2. Timing of Platelet Count Fall:
   • 2 points: Clear onset between days 5 and 10 of heparin exposure, or $\le 1$ day if heparin exposure occurred within the past 30 days.
   • 1 point: Consistent with day 5 to 10 fall, but missing platelet counts, or onset after day 10, or $\le 1$ day with heparin exposure within the past 30 to 100 days.
   • 0 points: Platelet fall occurs $< 4$ days without recent heparin exposure.
3. Thrombosis or Other Sequelae:
   • 2 points: Confirmed new thrombosis, skin necrosis at heparin injection sites, or acute systemic reaction after intravenous heparin bolus (chills, tachycardia, hypertension, dyspnea).
   • 1 point: Progressive or recurrent thrombosis, erythematous skin lesions, or suspected (unproven) thrombosis.
   • 0 points: None.
4. oTher Causes of Thrombocytopenia:
   • 2 points: No alternative cause evident.
   • 1 point: Possible alternative etiology identified (e.g., severe sepsis, post-cardiac surgery day 1 to 3, balloon pump).
   • 0 points: Definite alternative cause present.

Diagnostic Laboratory Testing

• PF4-Heparin Polyspecific or IgG-Specific ELISA: Highly sensitive ($> 99\%$) with a high negative predictive value. A negative ELISA virtually excludes HIT. However, false positives are frequent, particularly in cardiac surgery cohorts where non-activating antibodies arise. An optical density (OD) $> 0.40$ is considered positive, but higher values correlate directly with pathogenic potential (OD $> 2.0$ has a positive predictive value $> 90\%$).
• Serotonin Release Assay (SRA): The definitive gold-standard functional assay. Washed donor platelets are incubated with patient serum and varying concentrations of heparin. A positive SRA demonstrates $> 20\%$ $^{14}\text{C}$-serotonin release at therapeutic heparin levels ($0.1 - 0.3\text{ U/mL}$) and inhibition of release at supratherapeutic heparin levels ($100\text{ U/mL}$). Clinicians must never delay treatment while awaiting SRA results.

Acute Management and Pharmacotherapy

1. Immediate Cessation of Heparin: Stop all UFH infusions, LMWH injections, heparin flushes, heparin-coated invasive vascular catheters (e.g., pulmonary artery catheters), and continuous renal replacement circuit flushes.
2. Immediate Initiation of Non-Heparin Anticoagulation: Even in the absence of documented thrombosis, therapeutic-dose non-heparin anticoagulation is mandatory because the risk of subsequent thrombosis exceeds $50\%$ over the ensuing 30 days:
   • Argatroban: Synthetic univalent direct thrombin inhibitor (DTI). Metabolized exclusively by the liver; preferred in patients with acute kidney injury or renal replacement therapy. Standard initial dose is $2\text{ mcg/kg/min}$ IV continuous infusion (reduced to $0.5\text{ mcg/kg/min}$ in moderate/severe hepatic impairment, heart failure, critical illness, or post-cardiac surgery). Monitored using activated partial thromboplastin time (aPTT), with a target of $1.5$ to $3.0$ times baseline (typically 45 to 90 seconds). Argatroban cross-reacts with prothrombin time reagents, significantly elevating the INR.
   • Bivalirudin: Bivalent reversible direct thrombin inhibitor. Cleared predominantly via enzymatic proteolysis ($80\%$) with minor renal elimination ($20\%$). Preferred in patients with hepatic dysfunction or in those requiring acute percutaneous coronary intervention or cardiopulmonary bypass. Initial dose is $0.15 - 0.2\text{ mg/kg/h}$, titrated to an aPTT of $1.5$ to $2.5$ times baseline.
   • Fondaparinux & DOACs: Off-label alternatives used in hemodynamically stable, non-critically ill patients without renal compromise.

---

Disseminated Intravascular Coagulation (DIC)

Disseminated Intravascular Coagulation is a secondary clinicopathologic syndrome marked by systemic, uncontrolled intravascular activation of coagulation, leading to microvascular fibrin deposition, tissue ischemia, multi-organ dysfunction, and eventual exhaustion of platelets and clotting factors, culminating in severe hemorrhagic diathesis.

Etiologies and Pathophysiology

Common triggers include severe sepsis (endotoxin and cytokine-mediated tissue factor expression), major trauma, crush injury, acute pancreatitis, obstetrical catastrophes (amniotic fluid embolism, abruptio placentae), severe burns, acute promyelocytic leukemia, and metastatic adenocarcinomas. The central driver is unregulated thrombin generation resulting from excessive tissue factor-factor VIIa pathway activation, accompanied by severe downregulation of endogenous anticoagulant pathways (antithrombin III, protein C, tissue factor pathway inhibitor) and impaired fibrinolysis due to sustained plasminogen activator inhibitor-1 (PAI-1) release.

Diagnostic Scoring (ISTH Overt DIC Criteria)

The International Society on Thrombosis and Haemostasis (ISTH) overt DIC score utilizes four readily accessible laboratory parameters in patients with an identifiable underlying disorder:

• Platelet count: $> 100 \times 10^9/\text{L}$ (0 pts); $50$ to $100 \times 10^9/\text{L}$ (1 pt); $< 50 \times 10^9/\text{L}$ (2 pts).
• Fibrin-related markers (D-dimer / FDP): No increase (0 pts); moderate increase (2 pts); strong increase (3 pts).
• Prolonged prothrombin time (PT): $< 3\text{ s}$ prolongation (0 pts); $3$ to $6\text{ s}$ prolongation (1 pt); $> 6\text{ s}$ prolongation (2 pts).
• Fibrinogen level: $> 100\text{ mg/dL}$ (0 pts); $< 100\text{ mg/dL}$ (1 pt).

A cumulative score $\ge 5$ points is diagnostic of overt DIC and correlates with high intensive care unit mortality.

Targeted ICU Transfusion Protocols in DIC

Definitive therapy requires immediate eradication of the underlying etiology (source control, antimicrobial therapy, delivery of the placenta, surgical repair). Routine transfusion to correct abnormal laboratory values in non-bleeding patients is not recommended. When active bleeding or an invasive procedural requirement occurs, supportive therapy follows explicit targets:

1. Fibrinogen Replacement Target: Fibrinogen is an acute-phase reactant; a normal or borderline low level in severe sepsis or trauma indicates rapid consumption. Maintain fibrinogen $> 150\text{ mg/dL}$ (or $> 200\text{ mg/dL}$ in severe obstetric hemorrhage or trauma). Cryoprecipitate is the intervention of choice: 1 adult pool (10 units) provides approximately $2$ to $3\text{ g}$ of fibrinogen along with factor VIII, von Willebrand factor, and factor XIII, typically increasing plasma fibrinogen by $50$ to $100\text{ mg/dL}$. Fibrinogen concentrate ($30 - 60\text{ mg/kg}$) is an equivalent alternative when volume overload is a concern.
2. Platelet Transfusion Target: Transfuse to maintain platelets $\ge 50 \times 10^9/\text{L}$ in actively bleeding patients or those requiring major invasive interventions. In non-bleeding patients, prophylactic transfusion is reserved for counts $< 10$ to $20 \times 10^9/\text{L}$.
3. Coagulation Factor Replacement: Administer Fresh Frozen Plasma (FFP, $15 - 25\text{ mL/kg}$) in actively bleeding patients with significant PT/INR ($> 1.5 - 2.0$) or aPTT prolongation. Prothrombin complex concentrates (4F-PCC) are generally avoided in DIC due to thrombogenic risks from procoagulant factor accumulation in the absence of balanced anticoagulant replenishment.
4. Antifibrinolytic Contraindication: Tranexamic acid (TXA) and aminocaproic acid are contraindicated in classic sepsis-induced or prothrombotic DIC because blocking fibrinolysis while systemic microvascular thrombosis is active causes fatal organ ischemia, such as bilateral renal cortical necrosis. Antifibrinolytics are reserved solely for hyperfibrinolytic DIC phenotypes (e.g., acute promyelocytic leukemia or documented severe hyperfibrinolysis on thromboelastography).

---

Thrombotic Microangiopathies: TTP vs. HUS

Thrombotic Microangiopathies (TMAs) are characterized by the clinical triad of microangiopathic hemolytic anemia (MAHA), consumptive thrombocytopenia, and microvascular thrombosis causing ischemic organ injury.

Thrombotic Thrombocytopenic Purpura (TTP)

TTP is caused by a severe deficiency of ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) activity to $< 10\%$. Under physiological conditions, ADAMTS13 cleaves ultra-large von Willebrand factor (UL-vWF) multimers secreted by endothelial cells. In the absence of functional ADAMTS13—most commonly due to acquired IgG autoantibodies—UL-vWF multimers accumulate, tethering circulating platelets under high vascular shear stress. This produces disseminated platelet-rich microthrombi in arterioles and capillaries without significant activation of the soluble coagulation cascade (coagulation times, PT/INR, aPTT, and fibrinogen remain typically normal).

Clinical Presentation and Diagnostic Stratification

The historic pentad of TTP (thrombocytopenia, MAHA, fluctuating neurologic symptoms, fever, renal dysfunction) is present in $< 10\%$ of patients. Modern diagnosis requires only the dyad of unexplained microangiopathic hemolytic anemia (schistocytes on peripheral blood smear, high LDH, low/undetectable haptoglobin, negative direct antiglobulin test) and profound thrombocytopenia.

The PLASMIC Score predicts severe ADAMTS13 deficiency ($< 10\%$):

• Platelet count $< 30 \times 10^9/\text{L}$ (1 pt)
• Combined hemolysis markers (reticulocyte count $> 2.5\%$, undetectable haptoglobin, or indirect bilirubin $> 2.0\text{ mg/dL}$) (1 pt)
• No active cancer within past year (1 pt)
• No history of solid organ or stem cell transplant (1 pt)
• MCV $< 90\text{ fL}$ (1 pt)
• INR $< 1.5$ (1 pt)
• Serum creatinine $< 2.0\text{ mg/dL}$ (1 pt)

A PLASMIC score of 6 to 7 indicates high probability ($62\% - 82\%$) of severe ADAMTS13 deficiency and mandates immediate empiric intervention prior to receiving definitive ADAMTS13 laboratory results.

Emergent TTP Management Protocol

1. Therapeutic Plasma Exchange (TPE): Emergent daily $1.0$ to $1.5$ plasma volume exchanges with FFP or cryosupernatant plasma. TPE removes anti-ADAMTS13 autoantibodies and circulating UL-vWF multimers while replenishing active ADAMTS13 enzyme. Initiating TPE within hours of presentation reduces mortality from $> 90\%$ to $< 15\%$.
2. Systemic Immunosuppression: High-dose intravenous methylprednisolone ($1\text{ g/day}$ for 3 days or $1\text{ mg/kg/day}$) to suppress anti-ADAMTS13 antibody synthesis, coupled with early administration of Rituximab ($375\text{ mg/m}^2$ weekly for 4 doses).
3. Caplacizumab: A bivalent humanized nanobody that targets the A1 domain of vWF, inhibiting the interaction between UL-vWF and the platelet glycoprotein Ib-IX-V receptor. Administered as an initial $10\text{ mg}$ IV bolus prior to plasma exchange, followed by daily $11\text{ mg}$ subcutaneous injections (US labeling; $10\text{ mg}$ in Europe) post-TPE and continued for 30 days following cessation of TPE. Caplacizumab rapidly arrests platelet aggregation, shortens time to platelet count normalization, and dramatically lowers TTP exacerbations and refractoriness.
4. Absolute Avoidance of Platelet Transfusions: Platelet transfusions in TTP are strictly contraindicated because they provide substrate for accelerated microvascular thrombosis, precipitating acute myocardial infarction, stroke, and sudden cardiac death. Platelets are administered only in the presence of immediate life-threatening hemorrhage (e.g., catastrophic intracranial hemorrhage).

---

Anticoagulant Reversal in Life-Threatening Hemorrhage

Immediate reversal of systemic anticoagulation is essential in patients presenting with intracranial hemorrhage, massive gastrointestinal bleeding, or requiring emergency surgical interventions.